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a  b  s  t  r  a  c  t
Very  late stent  thrombosis  is  a feared  complication  after  drug-eluting  stent  (DES)  implantation.  Several
factors related  to the  patient,  generation  and  type  of  the  deployed  stent,  procedure,  and  premature
antiplatelet  withdrawal  are  known  to  contribute  to  this  complication.  Herein,  we describe  a  case  of a
Jehovah’s  witness  patient  who  developed  simultaneous  two-vessel  1st  generation  DES thrombosis  5.4
and 3.5  years  after  deployment  [with  sparing  of  the bare  metal  stent  (BMS)]  in the immediate  post-
operative  period  secondary  to  clopidogrel  withdrawal.  The  case  was  complicated  by ST-segment  elevation
myocardial  infarction,  cardiogenic  shock,  and  a ventricular  ﬁbrillation  cardiac  arrest  requiring  urgentery late stent thrombosis
ehovah’s witness
percutaneous  coronary  intervention.  The  acute  thrombosis  of  DESs  with  sparing  of the  BMS  exemplify
how  they  are  more  prone  to this  complication  due  to delayed  endothelialization  of  stent  struts  and
neoinitimal  coverage.
<Learning  objective:  Extreme  caution  should  be  excercised  when  attempting  to  withdraw  antiplatelets
immediately  before  surgery  in  patients  with  drug  eluting  stents  even  if  the  recomended  12-month  period
of  dual  antiplatelet  therapy  has  elapsed  because  of the risk  of very  late stent  thrombosis.>
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Despite the prominent success of drug-eluting stents (DESs)
ver bare metal stents (BMS) in suppressing neointimal prolifer-
tion and reducing in-stent restenosis, recent concerns have risen
ecause of the higher risk of late (31 days–1 year) and very late
after 1 year) DES thrombosis. The risk of stent thrombosis increases
n the perioperative period secondary to catecholamine production
romoting vasospasm, increased platelet activation, and decreased
brinolysis. Moreover, preoperative interruption of antiplatelet
herapy to minimize blood loss can trigger a rebound increase
n platelet activation further intensifying the chance of stent
hrombosis. The American College of Cardiology (ACC)/American
eart Association (AHA) recommends continuing dual antiplatelet
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therapy (DAPT) for 12 months after DES deployment because of lack
of evidence for protection beyond that period in randomized trials
and this recommendation has aptly guided percutaneous coronary
intervention (PCI) care over the past decade. The perioperative
period is a unique state with lack of clear-cut recommendations for
patients with DES deployed >12 months who  are still on antiplatelet
therapy and anticipating surgery. In this instance, the choice to
withhold antiplatelet therapy preoperatively to minimize blood
loss or continue them to avoid cardiovascular complications is
challenging. The presented case draws attention to the entity of
very late DES thrombosis in the postoperative period and invites
further research for ideal perioperative handling of antiplatelet
therapy.
Case reportA 54-year-old man  with a past medical history of hyperten-
sion, dyslipidemia, paroxysmal atrial ﬁbrillation, obstructive sleep
apnea, and coronary artery disease presented to the hospital for
elective bilateral knee replacement. He had 3 previous stents
vier Ltd. All rights reserved.
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eployed for recurrent anginal chest pains: in February 2003, a
MS  2.75/12 mm Express II (Boston Scientiﬁc, Natick, MA,  USA)
or a 90% mid  left anterior descending (LAD) lesion; in October
003, a sirolimus-eluting stent (SES) 3.5/13 mm Cypher (Cordis
orporation, Johnson & Johnson, Warren, NJ, USA) for a 90% mid  cir-
umﬂex (LCX) lesion; and in September 2005, a paclitaxel-eluting
tent (PES) 3/8 mm Taxus (Boston Scientiﬁc) for an 80% proximal
AD lesion. His last coronary angiography in July 2007 revealed no
cclusive disease. He denied any exertional chest pain or shortness
f breath and was compliant with his medications including war-
arin (for atrial ﬁbrillation), clopidogrel (sole antiplatelet agent),
otalol, and lisinopril. He was a Jehovah’s witness (JW) who would
ot receive any blood products. Given this cardiac history, he was
ent to his cardiologist for preoperative clearance. To minimize
lood loss, it was decided to stop clopidogrel ﬁve days prior to
urgery and to stop the warfarin and start low molecular weight
eparin bridging to be stopped 12 h prior to surgery and to continue
erioperative beta-blockade.
The patient’s surgery was scheduled on March 6th 2009 (73
onths after mid  LAD stent, 65 months after LCX stent, and 42
onths after proximal LAD stent). Following surgery and in the
ost anesthesia care unit, he started experiencing chest pain. Elec-
rocardiogram revealed ST-segment elevation in leads V5 and V6
ith ST-segment depression in leads V1–V3 conforming to a lateral
all ST-segment elevation myocardial infarction (STEMI) (Fig. 1).
hortly thereafter, he became unresponsive due to ventricular
brillation cardiac arrest requiring repeated deﬁbrillation (Fig. 2).
ollowing restoration of spontaneous circulation, dopamine and
orepinephrine were initiated for cardiogenic shock and the tra-
hea was intubated and the patient was mechanically ventilated
nd transferred to the catheterization suite. Coronary angiography
evealed total LCX occlusion with a thrombus at the site of the pre-
ious DES and a 90% stent thrombosis in the proximal LAD DES with
paring of the mid  LAD BMS  which showed only in-stent resteno-
is (Fig. 3). AngioJet thrombectomy (Medrad Inc., Warrendale, PA,
SA) was used to debulk the thrombus load in the LCX. There was
till signiﬁcant thrombus burden, so dilatation of the LCX stent was
erformed using a Quantum Maverick 3/15 mm balloon (Boston
cientiﬁc) at 9 atmospheres. A Driver 3.5/18 mm BMS  (Medtronic,
anta Rosa, CA, USA) was then successfully deployed followed by
ig. 1. Electrocardiogram during chest pain revealing ST-segment elevation in leads V5, V6
yocardial infarction. Notice also the subtle ST-segment elevation in the inferior leads.logy Cases 9 (2014) 57–60
thrombolysis in myocardial infarction (TIMI) 3 ﬂow. The same Mav-
erick was used to dilate the thrombus laden stent in the proximal
LAD; post-percutaneous transluminal coronary angioplasty (PTCA)
there was a TIMI 3 ﬂow. The patient experienced multiple episodes
of ventricular ﬁbrillation during the procedure requiring cardiopul-
monary resuscitation and multiple electrical deﬁbrillations. He was
given clopidogrel 600 mg,  aspirin 300 mg,  bivalirudin, and an intra-
aortic balloon pump was placed to augment coronary perfusion.
The patient had a peak troponin level of 600 g/L (this signiﬁcant
leak is likely related to repeated deﬁbrillation) and a left ventricular
ejection fraction of 20% prior to discharge. His condition gradu-
ally improved and he was  discharged when stable two weeks after
surgery.
Discussion
Despite the distinct success of DES compared to BMS  in sup-
pressing neointimal proliferation and reducing rates of in-stent
restenosis, the signiﬁcantly higher risk of very late DES  thrombosis
remains a major concern [1]. The various proposed mechanisms
of very late DES thrombosis include delayed endothelialization
and neoinitimal coverage, intrastent hypersensitivity reaction
to polymers [2], stent fracture [3], and late stent malapposition
[4]. Incomplete stent apposition is highly prevalent in patients
with very late DES thrombosis compared with respective controls
(77% vs. 12%; p < 0.001), suggesting a role in the pathogenesis of
this adverse event [5]. Imai and colleagues demonstrated that
peri-stent contrast staining (PSS) (deﬁned as an abnormal angiog-
raphic ﬁndings at sites of DES implantation, suggesting contrast
staining outside the stent struts) found within 12 months after
SES implantation was  associated with very late stent thrombosis
(8.2% in PSS vs. 0.2% in non-PSS) [6]. In an in vivo case-controlled
study by Guagliumi and colleagues, the presence of positive vessel
remodeling as imaged by intravascular ultrasound was associated
with late stent thrombosis after DES implantation (p = 0.003) [7].
Cessation of DAPT remains the single most important predictor of
stent thrombosis [8] and can trigger a rebound increase in platelet
activation [9,10]. This is especially concerning in the perioper-
ative period due to the accompanying increased catecholamine
 with reciprocal ST-segment depression in V1–V3 suggestive of a lateral ST-elevation
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Fig. 2. Rhythm strip revealing ventricular ﬁbrillation.
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tent  thrombosis of the proximal LAD stent (white arrow) with sparing of the mid-
roduction, vasospasm, increased platelet activation, and
ecreased ﬁbrinolysis creating a hypercoagulable state.
The ACC/AHA guidelines recommend at least 12 months of DAPT
fter DES deployment to avoid stent thrombosis and hence delaying
ny surgery whenever possible > 1 year [11].
The literature has reports of single-vessel [12] and simulta-
eous two-vessel [13], and triple-vessel very late DES thrombosis
14]. Most of these cases are related to 1st generation DESs. The
nd generation DESs appear to have reduced the incidence of
his feared complication because of better deliverability, however,
ery late stent thrombosis was also reported in a case 31 months
fter everolimus-eluting stent (EES) implantation due to acciden-
al aspirin discontinuation [15]. The fact that thrombosis can occur
imultaneously at multiple sites can be hypothesized by a gener-
lized thrombotic state that is created causing the simultaneous
ulti-vessel thrombosis.
An important challenge arises when a JW – who  would not
eceive any blood products – is anticipating surgery. In this
nstance, physicians tend to avoid any preoperative antiplatelets or
nticoagulants and utilize techniques to promote “bloodless” sur-
ical procedures (e.g. recombinant factors, biological products, cell
aver, isovolemic hemodilution, erythropoietin, intravenous iron,
nd balloon occlusion). In the presented case, the fear of intraoper-
tive bleeding in a JW patient with stable coronary artery disease
nd last DES deployed 42 months earlier, favored the cessation of
lopidogrel 5 days prior to surgery. This exposed the patient to
imultaneous acute thrombosis of the 2 DESs that were deployed
5 months and 42 months earlier, causing a lateral STEMI and car-
iogenic shock. In the same setting, an interesting observation was
he sparing of the mid-LAD BMS  which exempliﬁed how DES are
ore prone to this complication.
Very late stent thrombosis is known to occur with DES rather
han BMS. In a meta-analysis by Bavry and colleagues of 6675
atients randomized to DES vs. BMS, the incidence of very late
hrombosis was 5 events per 1000 DES patients but no events in
MS  patients (risk ratio = 5.02, p = 0.02). They also found that the
ncidence of very late thrombosis was 3.6 events per 1000 SES
atients and 5.9 events per 1000 PES patients [16]. Recent studies proximal left anterior descending artery (LAD) stents (arrows) (A). Panel B reveals
ent which shows in-stent restenosis (black arrow).
suggest a lower risk of stent thrombosis with second generation
DES. Smits and colleagues compared the Xience EES (Abbott Vas-
cular, SantaClara, CA, USA) with the Taxus Liberté PES at 2-year
follow-up and concluded a signiﬁcantly lower rate of stent throm-
bosis (0.9% vs. 3.9%; relative risk: 0.23; 95% CI: 0.11–0.49) [17].
Similarly, Stone and colleagues concluded a lower incidence of stent
thrombosis with EES vs. PES (0.4% vs. 1.2%, p = 0.008) [18]. Other
studies have also shown lower rates of very late stent thrombo-
sis with EES [19] and zotarolimus eluting stent (ZES) [20] when
compared to SES. Therefore, these second-generation stents are
associated with a superior long-term safety compared to ﬁrst-
generation stents (used in the present case).
We  aim with this report to draw attention to this cata-
strophic complication of DES thrombosis as a consequence of
stopping antiplatelet therapy in the perioperative period in patients
with DES. A question to be answered is whether discontinuing
antiplatelet therapy after 12 months can be generalized to all
patients with DES particularly in those awaiting surgery and who
are still receiving antiplatelets. In our opinion, patients with DES
who are still on DAPT and are anticipating surgery should be
approached more cautiously, even if the recommended 1 year
period of DAPT has elapsed. In JW patients the risk of operative
bleeding should be carefully weighed against the potential for
acute DES thrombosis. Implementing other techniques to minimize
blood loss in this instance is safer and rather recommended. Very
late stent thrombosis due to preoperative antiplatelet withdrawal
remains a major concern with DES that warrants further studies for
ideal perioperative antiplatelet handling.
Conﬂict of interest
Authors declare no conﬂict of interest.References
[1] Roukoz H, Bavry AA, Sarkees ML,  Mood GR, Kumbhani DJ, Rabbat MG,  Bhatt DL.
Comprehensive meta-analysis on drug-eluting stents versus bare-metal stents
during extended follow-up. Am J Med  2009;122(581):e1–10.
6  Cardio
[
[
[
[
[
[
[
[
[
[0 H.R. Omar et al. / Journal of
[2] Nebeker JR, Virmani R, Bennett CL, Hoffman JM,  Samore MH, Alvarez J, Davidson
CJ, McKoy JM,  Raisch DW,  Whisenant BK, Yarnold PR, Belknap SM,  West DP,
Gage JE, Morse RE, et al. Hypersensitivity cases associated with drug-eluting
coronary stents: a review of available cases from the Research on Adverse Drug
Events and Reports (RADAR) project. J Am Coll Cardiol 2006;47:175–81.
[3] Sianos G, Hofma S, Ligthart JM,  Saia F, Hoye A, Lemos PA, Serruys PW.  Stent
fracture and restenosis in the drug-eluting stent era. Catheter Cardiovasc Interv
2004;61:111–6.
[4] Choi BR, Lee CW,  Park SW.  Late stent thrombosis associated with late
stent malapposition after drug-eluting stenting: a case report. Korean Circ J
2006;36:472–5.
[5] Cook S, Wenaweser P, Togni M,  Billinger M,  Morger C, Seiler C, Vogel R, Hess O,
Meier B, Windecker S. Incomplete stent apposition and very late stent throm-
bosis after drug-eluting stent implantation. Circulation 2007;115:2426–34.
[6] Imai M,  Kadota K, Goto T, Fujii S, Yamamoto H, Fuku Y, Hosogi S, Hirono
A,  Tanaka H, Tada T, Morimoto T, Shiomi H, Kozuma K, Inoue K, Suzuki
N,  et al. Incidence, risk factors, and clinical sequelae of angiographic peri-
stent contrast staining after sirolimus-eluting stent implantation. Circulation
2011;123:2382–91.
[7] Guagliumi G, Sirbu V, Musumeci G, Gerber R, Biondi-Zoccai G, Ikejima H, Ladich
E, Lortkipanidze N, Matiashvili A, Valsecchi O, Virmani R, Stone GW.  Examina-
tion of the in vivo mechanisms of late drug-eluting stent thrombosis ﬁndings
from optical coherence tomography and intravascular ultrasound imaging.
JACC Cardiovasc Interv 2012;5:12–20.
[8] Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM,  Stankovic G, Airoldi F,
Chieffo A, Montorfano M, Carlino M,  Michev I, Corvaja N, Briguori C, Gerckens U,
Grube E, et al. Incidence, predictors, and outcome of thrombosis after successful
implantation of drug-eluting stents. JAMA 2005;293:2126–30.
[9] Collet JP, Montalescot G, Blanchet B, Tanguy ML,  Golmard JL, Choussat R, Beygui
F,  Payot L, Vignolles N, Metzger JP, Thomas D. Impact of prior use or recent with-
drawal of oral antiplatelet agents on acute coronary syndromes. Circulation
2004;110:2361–7.
10] Ferrari E, Benhamou M,  Cerboni P, Marcel B. Coronary syndromes following
aspirin withdrawal: a special risk for late stent thrombosis. J Am Coll Cardiol
2005;45:456–9.
11] King 3rd SB, Smith Jr SC, Hirshfeld Jr JW,  Jacobs AK, Morrison DA, Williams
DO, Feldman TE, Kern MJ,  O’Neill WW,  Schaff HV, Whitlow PL, ACC/AHA/SCAI,
Adams CD, Anderson JL, Buller CE, et al. 2007 focused update of the
[logy Cases 9 (2014) 57–60
ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention:
a  report of the American College of Cardiology/American Heart Association Task
Force on Practice guidelines. J Am Coll Cardiol 2008;51:172–209.
12] Panduranga P, Al-Mukhaini M.  Very late stent thrombosis of sirolimus-eluting
stent 59 months after implantation: a ﬁrst report from the Middle-East and
review of literature. Heart Views 2011;12:22–5.
13] Omar HR, Mangar D, Karlnoski R, Abdelmalak HD, Camporesi EM. Simulta-
neous left anterior descending and right coronary stent thrombosis after aspirin
withdrawal. Am J Emerg Med  2012;30(2093):e5–8.
14] Vieira MS,  Luz A, Anjo D, Antunes N, Santos M,  Carvalho H, Torres S.
Triple, simultaneous, very late coronary stent thrombosis. Rev Port Cardiol
2013;32:247–52.
15] Puri A, Saireddy R, McClean D. Simultaneous two-vessel very-late stent throm-
bosis of everolimus-eluting stents. J Invasive Cardiol 2013;25:E48–50.
16] Bavry AA, Kumbhani DJ, Helton TJ, Borek PP, Mood GR, Bhatt DL. Late thrombosis
of drug-eluting stents: a meta-analysis of randomized clinical trials. Am J Med
2006;119:1056–61.
17] Smits PC, Kedhi E, Royaards KJ, Joesoef KS, Wassing J, Rademaker-Havinga TA,
McFadden E. 2-year follow-up of a randomized controlled trial of everolimus-
and paclitaxel-eluting stents for coronary revascularization in daily practice.
COMPARE (Comparison of the everolimus eluting XIENCE-V stent with the
paclitaxel eluting TAXUS LIBERTÉ stent in all-comers: a randomized open label
trial). J Am Coll Cardiol 2011;58:11–8.
18] Stone GW,  Rizvi A, Sudhir K, Newman W,  Applegate RJ, Cannon LA, Maddux
JT,  Cutlip DE, Simonton CA, Sood P, Kereiakes DJ, SPIRIT IV Investiga-
tors. Randomized comparison of everolimus- and paclitaxel-eluting stents.
2-year follow-up from the SPIRIT (Clinical Evaluation of the XIENCE V
Everolimus Eluting Coronary Stent System) IV trial. J Am Coll Cardiol 2011;58:
19–25.
19] Räber L, Jüni P, Nüesch E, Kalesan B, Wenaweser P, Moschovitis A, Khattab AA,
Bahlo M,  Togni M,  Cook S, Vogel R, Seiler C, Meier B, Windecker S. Long-term
comparison of everolimus-eluting and sirolimus-eluting stents for coronary
revascularization. J Am Coll Cardiol 2011;57:2143–51.20] Yeung AC, Leon MB,  Jain A, Tolleson TR, Spriggs DJ, Mc Laurin BT, Popma JJ,
Fitzgerald PJ, Cutlip DE, Massaro JM,  Mauri L, RESOLUTE US Investigators. Clin-
ical evaluation of the Resolute zotarolimus-eluting coronary stent system in
the  treatment of de novo lesions in native coronary arteries: the RESOLUTE US
clinical trial. J Am Coll Cardiol 2011;57:1778–83.
